This is a genetic condition that affects how your body handles fats in your blood. It causes a buildup of cholesterol in the eyes, leading to a condition called 'fish eye disease'. It can also cause anemia (low red blood cells) and kidney problems. It's inherited from parents.
Every report comes from a Lived member, sent anonymously.
Have you had Kidney Transplant for Lecithin Cholesterol Acyltransferase Deficiency?
Lecithin cholesterol acyltransferase (LCAT) deficiency is a rare inherited condition in which the body lacks enough of a working enzyme called LCAT. In the blood, LCAT helps high-density lipoprotein (HDL), often called "good" cholesterol, collect cholesterol and carry it away from tissues. When the enzyme is missing or weak, HDL cholesterol falls to very low levels and unprocessed cholesterol and fats build up in places they should not, especially the cornea (the clear front surface of the eye), the kidneys and the membranes of red blood cells. There are two main forms. In familial LCAT deficiency, the enzyme works little or not at all. People typically develop clouding of the corneas, mild anemia from fragile red blood cells, and protein leaking into the urine that can progress to kidney failure. In fish-eye disease, the enzyme is only partly lost. Clouded corneas and very low HDL are the main features, and the kidneys are usually spared, which is why it tends to be recognized later in life. The line between the two is not always sharp: anemia and kidney problems have occasionally been reported in fish-eye disease, and different forms can even appear within one family.
LCAT deficiency is caused by changes (variants) in the LCAT gene, which carries the instructions for making the enzyme. It is inherited in an autosomal recessive pattern, meaning a person develops the condition only when both copies of the gene, one from each parent, are altered. Parents and other relatives who carry a single altered copy usually have no symptoms, although their HDL cholesterol may be somewhat lower than average. Because it is inherited, brothers and sisters of an affected person can be affected too, and symptoms can differ between relatives who share the same variants. The condition is not caused by diet, weight or lifestyle, and nothing a person does triggers it. Which specific gene change someone has does not reliably predict which form or how severe the disease will be. A separate, very rare acquired form occurs when the immune system makes antibodies that block the LCAT enzyme. It can look almost identical but is not inherited, and in reported cases steroid treatment such as prednisolone has restored enzyme activity.
LCAT deficiency is usually suspected when two findings occur together: clouded corneas and a very low HDL cholesterol level. For context, a healthy HDL level for adults is generally above 40 mg/dL for men and above 50 mg/dL for women. In people with familial LCAT deficiency, HDL is typically far lower, often under 10 mg/dL. Japanese specialists recommend testing LCAT activity when HDL is below 25 mg/dL and the corneas are cloudy. Because corneal clouding is often the first thing noticed, many people are diagnosed in adulthood after an eye examination, sometimes after years of unexplained findings. An eye doctor using a slit lamp (a microscope for examining the eye) can see grayish-white spots in the cornea. Specialized blood tests then measure how well LCAT works and how much of the cholesterol in the blood has been processed by it. These results help tell familial LCAT deficiency from fish-eye disease, because cholesterol processing on other blood particles is preserved in fish-eye disease but not in the complete form. These tests are available mainly at specialized laboratories. Other tests look for complications: a blood count for anemia and abnormally shaped red blood cells, urine tests for protein, and blood tests of kidney function. A kidney biopsy is sometimes done when protein is found in the urine. Genetic testing that finds two altered copies of the LCAT gene confirms the diagnosis. Clinicians also consider other inherited causes of very low HDL, such as Tangier disease, which can cloud the cornea as well.
There is no approved treatment that replaces the missing enzyme, so care focuses on slowing kidney damage and managing complications. For familial LCAT deficiency, a low-fat diet is often recommended. Small reports suggest it may reduce the abnormal fat particles thought to injure the kidneys and delay kidney problems, although it does not work for everyone. Doctors also commonly prescribe blood pressure medicines called ACE inhibitors (angiotensin-converting enzyme inhibitors) or ARBs (angiotensin II receptor blockers), which can reduce the amount of protein leaking into the urine. Cholesterol-lowering medicines, diuretics (water pills) and steroids have also been used, but the evidence for every one of these approaches comes from individual cases and small series rather than clinical trials. When kidneys fail, dialysis or a kidney transplant is needed. When corneal clouding seriously limits vision, a corneal transplant can help. In both cases the disease tends to return in the new tissue over time, because the body still lacks the enzyme. Transfusions of plasma raise LCAT activity only briefly, falling back within about a week, so they are not a practical long-term option. For fish-eye disease, which usually spares the kidneys, care centers on eye health and on managing heart risk factors. Treatments aimed at the underlying cause are still experimental. An enzyme replacement made in the laboratory somewhat improved anemia, kidney measures and HDL in a US study, but the effect faded within two weeks and would need repeated doses. Gene and cell therapy is being studied in Japan and is not approved anywhere.
LCAT deficiency is lifelong, and its course varies widely, even within a family. In familial LCAT deficiency, the kidneys largely determine the long-term outlook. Protein in the urine can appear in childhood and kidney function tends to decline over decades. In an Italian group of patients, the median age at which a serious kidney event occurred (needing dialysis, a transplant, or death from kidney disease) was 46, but some people progress more slowly and a few do not develop significant kidney disease at all. Kidney damage often causes no symptoms until it is advanced, so regular urine and blood tests are the main way to track it, usually with a kidney specialist. Corneal clouding usually develops slowly. Some people notice reduced sharpness, glare or difficulty seeing contrast, and for others it eventually affects vision enough to consider a transplant. The anemia is usually mild. Whether LCAT deficiency raises the risk of heart disease is still debated: a large review of published cases found premature coronary heart disease more often in fish-eye disease, so checking and managing blood pressure, smoking and other heart risk factors is a reasonable part of care, particularly in that form. Because the condition is so rare, few long-term studies exist, and many people will be followed by a lipid specialist, nephrologist and eye doctor working together. Genetic counseling can help relatives understand whether they might carry or have the condition.
Ask for an evaluation if an eye examination finds clouded corneas without a clear cause, especially alongside a very low HDL cholesterol result, or if a brother, sister or other relative has been diagnosed with LCAT deficiency or fish-eye disease. If you already have the diagnosis, contact your care team promptly when routine tests show more protein in your urine or a drop in kidney function, since that is the point at which treatment is reviewed and planning for possible dialysis or transplant begins. Tell your eye doctor if your vision, glare or contrast sensitivity worsens noticeably.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Lecithin Cholesterol Acyltransferase Deficiency is like, what's helped you, or ask the community a question.